Last reviewed · How we verify

Pharmacokinetics, Dosage of Niraparib

Hospices Civils de Lyon · FDA-approved active Biologic

Pharmacokinetics, Dosage of Niraparib is a PARP inhibitor Biologic drug developed by Hospices Civils de Lyon. It is currently FDA-approved for Ovarian cancer (platinum-sensitive recurrent, BRCA-mutated, and homologous recombination deficient), Metastatic breast cancer (BRCA-mutated), Prostate cancer (BRCA-mutated, metastatic castration-resistant).

Niraparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and leading to cell death.

Niraparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and leading to cell death. Used for Ovarian cancer (platinum-sensitive recurrent, BRCA-mutated, and homologous recombination deficient), Metastatic breast cancer (BRCA-mutated), Prostate cancer (BRCA-mutated, metastatic castration-resistant).

At a glance

Generic namePharmacokinetics, Dosage of Niraparib
SponsorHospices Civils de Lyon
Drug classPARP inhibitor
TargetPARP1, PARP2
ModalityBiologic
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Niraparib is a PARP inhibitor that blocks PARP1 and PARP2, enzymes critical for single-strand DNA break repair. By inhibiting PARP, the drug causes accumulation of DNA damage in cancer cells, particularly those with BRCA1/2 mutations or homologous recombination deficiency, triggering apoptosis. This mechanism is especially effective in ovarian and breast cancers with defective DNA repair pathways.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pharmacokinetics, Dosage of Niraparib

What is Pharmacokinetics, Dosage of Niraparib?

Pharmacokinetics, Dosage of Niraparib is a PARP inhibitor drug developed by Hospices Civils de Lyon, indicated for Ovarian cancer (platinum-sensitive recurrent, BRCA-mutated, and homologous recombination deficient), Metastatic breast cancer (BRCA-mutated), Prostate cancer (BRCA-mutated, metastatic castration-resistant).

How does Pharmacokinetics, Dosage of Niraparib work?

Niraparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and leading to cell death.

What is Pharmacokinetics, Dosage of Niraparib used for?

Pharmacokinetics, Dosage of Niraparib is indicated for Ovarian cancer (platinum-sensitive recurrent, BRCA-mutated, and homologous recombination deficient), Metastatic breast cancer (BRCA-mutated), Prostate cancer (BRCA-mutated, metastatic castration-resistant).

Who makes Pharmacokinetics, Dosage of Niraparib?

Pharmacokinetics, Dosage of Niraparib is developed and marketed by Hospices Civils de Lyon (see full Hospices Civils de Lyon pipeline at /company/hospices-civils-de-lyon).

What drug class is Pharmacokinetics, Dosage of Niraparib in?

Pharmacokinetics, Dosage of Niraparib belongs to the PARP inhibitor class. See all PARP inhibitor drugs at /class/parp-inhibitor.

What development phase is Pharmacokinetics, Dosage of Niraparib in?

Pharmacokinetics, Dosage of Niraparib is FDA-approved (marketed).

What are the side effects of Pharmacokinetics, Dosage of Niraparib?

Common side effects of Pharmacokinetics, Dosage of Niraparib include Anemia, Thrombocytopenia, Nausea, Fatigue, Vomiting, Constipation.

What does Pharmacokinetics, Dosage of Niraparib target?

Pharmacokinetics, Dosage of Niraparib targets PARP1, PARP2 and is a PARP inhibitor.

Related